PwCs consumer research of roughly 3,000 people found that GLP-1 users spent about 11% less on most food categories overall, and at the scale of adoption now underway, those individual household changes aggregate into the revenue reduction JPMorgan estimates at between $30 billion and $55 billion for the food and beverage industry by 2030 to 2034
Retatrutide promises big weight loss, but safety remains a question
What side effects are most common, and when do they improve
Some researchers transition to other fat loss peptides or longevity-focused protocols after completing a retatrutide cycle, using the metabolic improvements as a foundation for further optimization
The FDA has set out specific clinical benchmarks for drug approval for NASH
GLP-1 may also affect hunger centers in the brain, which impacts appetite regulation and reduces hunger